511 results on '"Fröhling S"'
Search Results
52. Klassische und molekulare Zytogenetik in der Hämatologie und Onkologie: Bedeutung, Techniken und klinische Anwendung
53. Cutaneous epithelioid haemangiomas show somatic mutations in the mitogen‐activated protein kinase pathway.
54. Dauerhaftes Ansprechen auf Olaparib und endokrine Therapie bei einer Patientin mit metastasiertem luminalem Mammakarzinom und gBRCA-Mutation
55. Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial
56. Improving personalised therapy in metastatic breast cancer by implementing RNA sequencing based gene expression signatures
57. Comprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German Cancer Consortium
58. Community-driven development of a modified progression-free survival ratio for precision oncology trials
59. EORTC SPECTA-AYA: A molecular profiling platform for adolescents and young adults with cancer in Europe
60. Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring dna repair deficiencies
61. Functional genomic approaches to identify novel therapeutic targets: V845
62. Intensive consolidation versus oral maintenance therapy in patients 61 years or older with acute myeloid leukemia in first remission: results of second randomization of the AML HD98-B treatment Trial
63. Cooperative analysis of patient with acute myeloid leukaemia exhibiting a normal karyotype treated within the German multicentre treatment trials AML-2/95, AML-1/99, AMLHD93 and AMLHD98A
64. Treatment of Acute Myeloid Leukaemia (AML) and High-Risk Myelodysplastic Syndromes (MDS) with the Histone Deacetylase Inhibitor Valproic Acid (VA) in Combination with All-Trans Retinoic Acid (ATRA): O393
65. Acute Myeloid Leukemia with Deletion 9q is Associated with CEBPA Loss-of-Function Mutations: O374
66. Pretreatment Cytogenetic Abnormalities are Predictive of Induction Success, Cumulative Incidence of Relapse and Overall Survival in Patients - 60 Years of Age with Newly Diagnosed Acute Myeloid Leukemia: O93
67. Gene Expression Profiling Based Identification of Distinct inv(16) Subclasses in Adult Acute Myeloid Leukemia: O90
68. Cooperative Analysis of Patient with Acute Myeloid Leukemia Exhibiting a Normal Karyotype Treated within the German Multicenter Treatment Trials AML-2/95, AML-1/99, AMLHD93 and AMLHD98A: O91
69. Design and evaluation of a real-time RT-PCR assay for the detection of minimal residual disease in MLL/AF9-positive acute myeloid leukemias: P588
70. Mutation analysis of the transcription factor PU.1 in younger adults (16 to 60 years) with acute myeloid leukemia: A study of the AML Study Group Ulm: P561
71. Identification and molecular characterization of a candidate gene located in the commonly deleted region 7q22-q31.1 in myeloid leukemias: V387
72. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations: V224
73. Phase III-study of all-trans retinoic acid in previously untreated patients 61 years or older with acute myeloid leukemia: AMLSG ULM study HD98B: V137
74. Identification and characterization of a novel gene located in the commonly deleted region 7q22-q31.1 in myeloid leukemias: 780
75. Partial tandem duplication of the MLL gene as an important prognostic factor for remission duration in adult patients (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study within the multicenter treatment trials AML HD93 and HD98-A of the AML Study group Ulm (AMLSG ULM): 785
76. Prognostic significance of CEBPA mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group Ulm: 768
77. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML study group Ulm: 769
78. Early allogeneic transplantation in patients with high-risk acute myeloid leukemia defined by karyotype at diagnosis and response to first induction therapy: Results of the ongoing AML HD98A trial of the AML SG ULM: 35
79. Konnatales Glioblastom – Ein Fallbericht
80. TRANSCRIPTIONAL AND GENOMIC INTRA-TUMOR HETEROGENEITY DRIVES SUBCLONE SPECIFIC DRUG RESPONSES IN DIFFUSE LARGE B CELL LYMPHOMA
81. Reliability of the detection of the mutation burden status by targeted next generation sequencing applying a large gene panel
82. Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms
83. PO-451 Targeted proteomics to improve therapy stratification of cancer patients
84. 120TiP - EORTC SPECTA-AYA: A molecular profiling platform for adolescents and young adults with cancer in Europe
85. 97P - Community-driven development of a modified progression-free survival ratio for precision oncology trials
86. 81P - Comprehensive genomic and transcriptomic profiling in advanced-stage cancers and rare malignancies: Clinical results from the MASTER trial of the German Cancer Consortium
87. 70P - Improving personalised therapy in metastatic breast cancer by implementing RNA sequencing based gene expression signatures
88. 18P - Clinical outcome of personalised treatment guided by genome and transcriptome sequencing in patients with neuroendocrine neoplasms: Updated results from the German NCT/DKTK MASTER trial
89. 1979TiP - Randomized phase II study of trabectedin/olaparib compared to physician’s choice in subjects with previously treated advanced or recurrent solid tumors harboring dna repair deficiencies
90. CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)
91. JUN is a key transcriptional regulator of the unfolded protein response in acute myeloid leukemia
92. Anti‐programmed cell death‐1 therapy in nonmelanoma skin cancer
93. 27P - Reliability of the detection of the mutation burden status by targeted next generation sequencing applying a large gene panel
94. 1310PD - Prospective genome and transcriptome sequencing in advanced-stage neuroendocrine neoplasms
95. Integration der Genomsequenzierung in die klinische Hämato-Onkologie – Eine Möglichkeit für „personalisierte“ Therapien
96. Dauerhafte Remission unter dualer HER2-Blockade mit Trastuzumab und Pertuzumab bei metastasiertem Gallenblasenkarzinom
97. Cooperation of BRAFF595L and mutant HRAS in histiocytic sarcoma provides new insights into oncogenic BRAF signaling
98. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia
99. 1526TiP - CDK4/6 inhibition in locally advanced/metastatic chordoma (NCT PMO-1601)
100. Protein kinase D2 modulates tumor growth and tumor angiogenic programme induced by heat shock protein 90
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.